BRANFORD, Conn. / Aug 22, 2023 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that Platinum™, the world’s first next-generation protein sequencing instrument, has been honored in Fast Company’s Innovation by Design Awards for 2023 in the Products category.
The Innovation by Design Awards, which can be found in the September 2023 issue of Fast Company, honor the designers and businesses solving the most crucial problems of today and anticipating the pressing issues of tomorrow. The competition, now in its 12th year, features a range of blue-chip companies, emerging startups, and hungry young talents. It is one of the most sought-after design awards in the industry.
“We are honored to have our first-to-market protein sequencing instrument highlighted on this year’s Fast Company: Innovation by Design list, but it would not be possible without our world class team of engineers and scientists who spent over a decade designing and developing Platinum,” said Jeff Hawkins, Chief Executive Officer of Quantum-Si. “For decades, proteomics research has relied on a team of technically advanced researchers, and large and expensive mass spectrometry machines. The beauty of Platinum’s design is that it takes this complex process, and places all these critical elements into a sleek and accessible benchtop instrument that is advancing our understanding of the human proteome, and thus our own biology.”
Platinum uses proprietary recognizers to identify amino acids of proteins using kinetic binding signatures. Its elegant design and simple workflow enable broad-scale access to proteomic data, for every scientist, everywhere, making it a groundbreaking platform for the future of proteomics research. With its compact benchtop design and low price-point, Platinum is poised to accelerate breakthroughs across scientific disciplines, from drug discovery to biotech, and help people live healthier and longer lives.
“So much innovation news these days is focused on AI,” said Brendan Vaughan, editor-in-chief of Fast Company. “This year’s Innovation by Design honorees are a reminder that it’s human ingenuity that drives invention.”
Winners, finalists, and honorable mentions are featured online, and winners and finalists are featured in the issue of Fast Company magazine, on newsstands August 29, 2023.
To see the complete list, go to https://www.fastcompany.com/innovation-by-design/list.
About Fast Company
Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication Inc., and can be found online at www.fastcompany.com.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at www.quantum-si.com.
Last Trade: | US$1.18 |
Daily Change: | 0.04 3.51 |
Daily Volume: | 2,964,245 |
Market Cap: | US$144.880M |
November 21, 2024 November 20, 2024 November 20, 2024 November 20, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB